Truist Securities keeps Buy rating on argenx after trial failure, 'We believe the stock reaction is overdone'
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall Street ends higher after Democrats win Congress; data center stocks tumble
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
| (NASDAQ: ARGX) | Delayed: 931.38 +30.26 (3.36%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $901.12 | 52 Week High | $ | |||
| Open | $922.71 | 52 Week Low | $ | |||
| Day High | $933.39 | P/E | N/A | |||
| Day Low | $895.49 | EPS | $ | |||
| Volume | 645,888 | |||||
